Suscribirse

Evora® chromium–cobalt dual mobility socket: Results at a minimum 10 years’ follow-up - 02/12/13

Doi : 10.1016/j.otsr.2013.07.017 
S. Leclercq a, , J.Y. Benoit b, J.P. de Rosa c, E. Tallier d, C. Leteurtre d, P.H. Girardin e
a Centre Hospitalier Saint-Martin, 18, rue des Roquemonts, 14050 Caen, France 
b Établissements Hospitaliers du Bessin, Site Nesmond, 13, rue de Nesmond, BP 18127, 14401 Bayeux, France 
c Centre Hospitalier Avranches Granville, 59, rue Liberté, 50300 Avranches, France 
d Centre Hospitalier Général, 2, rue de l’Hôpital, 14700 Falaise, France 
e Centre Hospitalier, route de Chatelneuf, BP 219, 42605 Montbrison, France 

Corresponding author. Tel.: +33 2 31 43 36 50; fax: +33 2 31 43 33 68.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Summary

Introduction

The Evora chromium–cobalt alloy dual mobility socket claims to display a large articulation tribology different from that of stainless steel models, limiting the risk of intraprosthetic dislocation and wear. The present study reports a minimum of 10years’ follow-up in a multicenter prospective series of 200 sockets previously reported on at 5years.

Hypothesis

The use of chromium–cobalt in dual mobility sockets provides a low rate of failure at 10years, especially as regards to osteolysis and intraprosthetic dislocation.

Materials and methods

Two hundred hydroxyapatite-coated molded chromium–cobalt sockets without titanium interface were implanted without cement in 194 patients with a mean age of 70years (range, 32–91years). Clinical results were assessed on Postel Merle d’Aubigné and Harris scores, plain radiographs and survival analysis.

Results

At a mean 11years’ follow-up (10–13years), 56 patients had died and 31 were lost to follow-up. Four underwent surgical revision (3 femoral components, and 1 socket for migration at 9years with complete disappearance of the hydroxyapatite). A total of 109 implants were analyzable in 107 patients with a mean age of 81years (55–93years). At follow-up, the mean Harris score was 90 (75–96) and the PMA score 16.3 (14–18). There were no cases of loosening (except for the case reoperated on at 9years) and no acetabular radiolucency or cysts. There were 2 cases of non-evolutive femoral radiolucency and 10 of femoral granuloma, involving head size > 22mm (P<0.0001) and a cemented titanium stem (P=0.004) as risk factors. There were no dislocations in the large or small articulation. Ten-year survival was 99% (95% CI: 97.3%–100%) with socket revision as censorship criterion.

Discussion

The absence of dislocation in both small and large articulations confirmed the efficacy of the dual mobility concept and suggested an advantage for chromium–cobalt sockets in reducing the rate of intraprosthetic dislocation and preventing blockage of the large articulation by a better performance in the friction couple. Granulomas were associated with wear in cemented titanium stems and with heads greater than 22mm in diameter. Ten-year survival was 99% (censorship criterion: revision for socket failure); there was, however, one case of socket loosening with disappearance of the hydroxyapatite, indicating that surveillance should be continued in this cohort.

Level of evidence

Level IV. Retrospective study.

El texto completo de este artículo está disponible en PDF.

Keywords : Total hip arthroplasty, Dual mobility, Socket, Dislocation


Esquema


© 2013  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 99 - N° 8

P. 923-928 - décembre 2013 Regresar al número
Artículo precedente Artículo precedente
  • High rate of fracture in the cementless modular Extrême™ (Mark I) femoral prosthesis in revision total hip arthroplasty: 33 cases at more than 5 years’ follow-up
  • J. Benoist, J.-C. Lambotte, J.-L. Polard, D. Huten
| Artículo siguiente Artículo siguiente
  • Predictors of postoperative outcome for acetabular fractures
  • U.K. Meena, S.K. Tripathy, R.K. Sen, S. Aggarwal, P. Behera

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.